sb2

SB273005 is an orally active and potent nonpeptide integrin αvβ3 antagonist that inhibits αvβ3 and αvβ5 and reduces the production of Th2 cells and the cytokine IL-10 in pregnant mice.

SB225002 is a potent and selective CXCR2 antagonist inhibiting interleukin IL-8 binding to CXCR2.

SB297006 is an antagonist of C-C chemokine receptor 3 (CCR3; IC50 = 39 nM), which normally is activated by eotaxin, eotaxin-3, MCP-3, MCP-4, RANTES, and MIP-1δ. It is at least 250-fold selective for CCR3 over a panel of other chemokine receptors. SB 297006 blocks CCR3-mediated calcium mobilization induced by eotaxin, eotaxin-2, and MCP-4 in transfected cells. It suppresses antigen-induced accumulation of Th2 lymphocytes and eosinophils in lungs of mice when delivered subcutaneously (100 mg/kg).

SB228357 is a potent and selective antagonist of the 5-HT receptor with pKis of 6.9, 8.0, and 9.0 for 5-HT2A, 5-HT2B, and 5-HT2C, respectively.

SB234551 is a selective antagonist of endothelin ETA receptor.

SB26019 is a potent anti-neuroinflammatory compound that modulates the activation of NF-κB by promoting the formation of monomeric α-tubulin, thereby hindering the translocation of p65 and regulating neuroinflammatory processes [1].

SB2602 selectively inhibits mTOR.

SB236057 is a potent and selective inverse agonist for the 5-HT receptor, acting especially at 5-HT autoreceptors on nerve terminals. It produces a rapid increase in 5-HT levels in the brain. SB236057 also acts as a potent teratogen, producing severe musc

SB269652 is the pioneering drug-like allosteric modulator of the dopamine D2 receptor.

SB290157 trifluoroacetate is a potent and selective antagonist of the C3a receptor, with an IC50 of 200 nM.

SB251023 is an agonist of β3-adrenoceptor.

ASB20123, a CNP/ghrelin chimeric peptide, promotes bone growth and has potential research applications in growth disorders and dwarfism [1].

SB220025, a specific and potent inhibitor of human p38 mitogen-activated protein kinase, reduces the production of tumor necrosis factor induced by lipopolysaccharide.

CAY10526 (BTH) is a selective mPGES-1 inhibitor that acts as an inhibitor of the NF-κB signaling pathway.